Curigliano G, O'Shaughnessy J, Bidard FC et al. Patient-reported outcomes (PROs) in patients with ER+, HER2- advanced breast cancer (ABC) treated with imlunestrant, investigator's choice standard endocrine therapy, or imlunestrant + abemaciclib: Results from the phase III EMBER-3 trial. J Clin Oncol 2025; 43 (16_suppl): 1001-1001.

0

PRE

AI

DOI：10.1200/jco.2025.43.16_suppl.1001

Original

Original request for help

Share

Save